top of page

Teva’s severe eosinophilic asthma drug Cinqaero wins EU approval

Teva Pharmaceutical Industries has announced that the European Commission has granted marketing authorisation for their asthma drug, Cinqaero (reslizumab) in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page